Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain
Roel E., Pistillo A., Recalde M., Sena AG., Fernández-Bertolín S., Aragón M., Puente D., Ahmed W-U-R., Alghoul H., Alser O., Alshammari TM., Areia C., Blacketer C., Carter W., Casajust P., Culhane AC., Dawoud D., DeFalco F., Duvall SL., Falconer T., Golozar A., Gong M., Hester L., Hripcsak G., Tan EH., Jeon H., Jonnagaddala J., Lai LYH., Lynch KE., Matheny ME., Morales DR., Natarajan K., Nyberg F., Ostropolets A., Posada JD., Prats-Uribe A., Reich CG., Rivera D., Schilling LM., Soerjomataram I., Shah K., Shah N., Shen Y., Spotniz M., Subbian V., Suchard MA., Trama A., Zhang L., Zhang Y., Ryan P., Prieto-Alhambra D., Kostka K., Duarte-Salles T.
AbstractPurposeWe aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.MethodsWe conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: i) diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.ResultsWe included 118,155 patients with a cancer history in the COVID-19 diagnosed and 41,939 in the COVID-19 hospitalized cohorts. The most frequent cancer subtypes were prostate and breast cancer (range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events.ConclusionPatients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.